ShangPharma pumps $60m into Qidong biologics plant for international clients

By Dan Stanton contact

- Last updated on GMT

Qidong is in the Jiangsu province
Qidong is in the Jiangsu province

Related tags: Biotechnology, Contract research organization, Pre-clinical development

China’s ShangPharma is building a $60m (€53m) single-use biologics manufacturing plant in Qidong, to be operated by its CMO subsidiary.

China Gateway Biologics, the contract manufacturing wing of Shanghai-based pharma firm ShangPharma, will operate the facility located in the Qidong Biopharma Industrial Zone.

“The [$60m] investment offers China Gateway Biologics the opportunity to grow to the next level as a full biopharmaceutical service provider from preclinical development to commercial scale,” ​ShamgPharma’s CEO Michael Hui said in a statement today.

“We strongly believe the state-of-the-art single use facility conforming to Western standards will be able to support our international client base.”

The plant will be equipped with a 500L single-use mammalian cell culture train for clinical phase supply and two 2000L trains for commercial manufacturing, with fill & finish capabilities also available on site.

The facility is the first built in the dedicated Qidong Biopharma Industrial Zone and the investment was described by Qidong's Party Secretary Xu Feng as “a big milestone to establish Qidong as a biotech hub at the door steps of Shanghai.”

The site will also have preclinical research capabilities which will be operated by ChemPartner – ShangPharma’s contract research organisation (CRO) business.

BeiGene in Suzhou

The news comes weeks after Beijing-based biopharma firm BeiGene announced it was building a 9,000m2 cGMP commercial biomanufacturing facility in the Suzhou Industrial Park (SIP) in Suzhou, China – about an hour West of Shanghai.

“This will be a truly cutting-edge, state of the art facility utilizing the leading technologies in biomanufacturing that will also meet the utmost regulatory standards,” ​the firm’s Head of Regulatory Affairs Wendy Yan said in August.

“Upon completion we will seek the necessary approvals to ensure our new site is fully compliant with regulatory procedures in all key global markets, including the United States, Europe and China.”

Related news

Related product

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars